F075 Skin Disease in Transplant Recipients and Immunosuppressed Patients
DESCRIPTION
Organ transplant recipients and other immunosuppressed patients have an increased risk of skin cancer development and increased risk of metastasis and death from skin cancer, as well as distinct presentations of inflammatory and infectious skin disease. Dermatologists are uniquely positioned to care for these patients and optimize treatment outcomes in the context of multidisciplinary care. This session will provide an overview of key issues in the care of immunosuppressed patients, with a focus on prevention, detection and management of multiple skin cancers as well as inflammatory and infectious skin disease.
LEARNING OBJECTIVES
Summarize recommendations for screening, detection and management of multiple skin cancers in transplant and immunosuppressed patients, recognizing the role of multidisciplinary care.
Prescribe topical and systemic field therapy for treatment of precursor lesions and prevention of skin cancer in transplant and immunosuppressed patients.
Differentiate inflammatory from infectious and neoplastic skin disease in transplant and immunosuppressed patients.
SCHEDULE
3:30 PM
Introduction and Overview
Sean Christensen, MD, PhD, FAAD
3:45 PM
Management of Low-Risk Skin Cancers
Joi B. Carter, MD, FAAD
4:00 PM
Field Treatment
Lauren Crow, MPH, MD, FAAD
4:15 PM
Systemic Chemoprevention
Basia M Michalski, MD, FAAD
4:30 PM
High Risk SCC
Kristin Bibee, MD, PhD, FAAD
4:45 PM
Immunotherapy for Advanced Cancer
Nathalie C. Zeitouni, MD, FAAD
5:00 PM
Melanoma and Rare Tumors
Kelsey Hirotsu, MD, FAAD
5:15 PM
Pediatric Skin Disease in Immunosuppression
Carrie C. Coughlin, MD, FAAD
DIRECTOR
Sean Christensen, MD, PhD, FAAD
SPEAKERS
Kristin Bibee, MD, PhD, FAAD
Joi B. Carter, MD, FAAD
Carrie C. Coughlin, MD, FAAD
Lauren Crow, MPH, MD, FAAD
Kelsey Hirotsu, MD, FAAD
Basia M Michalski, MD, FAAD
Nathalie C. Zeitouni, MD, FAAD
HANDOUTS
DISCLOSURES
Kristin Bibee, MD, PhD, FAAD
No financial relationships exist with ineligible companies.
Joi B. Carter, MD, FAAD
No financial relationships exist with ineligible companies.
Sean Christensen, MD, PhD, FAAD
Canfield Scientific, Inc. – Consultant (1099 relationship)(Fees); Castle Biosciences – Advisory Board(Honoraria); inhibitor therapeutics – Advisory Board(No Compensation Received); Sol-Gel Technologies – Investigator(Grants/Research Funding);
Carrie C. Coughlin, MD, FAAD
No financial relationships exist with ineligible companies.
Lauren Crow, MPH, MD, FAAD
No financial relationships exist with ineligible companies.
Kelsey Hirotsu, MD, FAAD
No financial relationships exist with ineligible companies.
Basia M Michalski, MD, FAAD
No financial relationships exist with ineligible companies.
Nathalie C. Zeitouni, MD, FAAD
Biofrontera AG – Investigator(Grants/Research Funding); Castle Biosciences – Investigator(Grants/Research Funding), Speaker(Honoraria); DermaSensor Inc – Investigator(Honoraria); MiMedx Group, Inc – Consultant(Honoraria); Regeneron Pharmaceuticals, Inc. – Speaker(Honoraria); Replimune – Investigator(Grants/Research Funding); Sanofi/Regeneron – Advisory Board(Honoraria), Speaker(Honoraria); Sun Pharmaceutical Industries Ltd. – Advisory Board(Honoraria), Investigator(Grants/Research Funding);